The study that was released on November 17 was IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Merck announced that the trial met its primary endpoint but specific results were not released until they were presented at the American Heart Association Scientific Sessions the same day. According to USA Today (11/17/14), more than 18,000 people were included in the study, which found that Vytorin lowered the risk of heart attack and stroke by approximately 6 percent in patients who suffered previous heart problems.
Forbes (11/17/14) notes that there was no difference between the treatment group and the control group in terms of overall deaths, including coronary or cardiovascular deaths, but there was a reduction in myocardial infarction, stroke and ischemic stroke.
In other words, patients who were at a high risk of suffering heart attack and stroke had fewer heart attacks, strokes or hospitalizations when they took Vytorin than those who took only a statin. But, critics note, a six percent reduction is not all that significant. Furthermore, on a fairly important endpoint - cardiovascular death - there was no difference between the groups.
Vytorin is used to lower LDL levels in patients as a way to prevent heart disease. Previous studies involving the drug had found that it was not as effective as a statin alone at preventing repeat heart problems. Merck and Schering-Plough, the companies who developed Vytorin, were also accused of hiding damaging study results back in 2007-2008.
READ MORE VYTORIN LEGAL NEWS
Right now, the headlines tout that Vytorin is effective, but the study that confirms this contradicts previous studies and has not been peer reviewed or published in a major scientific publication. These results are provided by the company that will benefit financially from a good result.